Stanford, California 94305

  • Breast Cancer

Purpose:

We hope to learn the value of the SPY ELITE® intra-operative angiography in reducing post-operative complications associated with low breast skin blood flow after breast reconstruction using implants.


Study summary:

Breast cancer is the most common malignancy among women, and over 180,000 women will be diagnosed with this disease in 2008. Last year, over 57,000 breast reconstructive procedures were performed, of which prosthetic reconstruction constituted 76%. Immediate reconstruction has been favored over delayed procedures for psychological and technical reasons. However, immediate breast reconstruction is associated with significantly higher complication rates (50-52%) than delayed procedures (32-36%), especially when a prosthetic technique is used. For prosthetic reconstructions, the most significant early complications include necrosis of the mastectomy skin flaps, infection, delayed wound healing and exposure of the implant. The published incidence of these complications ranges between 10% and 40% and is predominantly associated with malperfusion of mastectomy skin flaps. Thus, evaluation of skin perfusion and elimination of poorly vascularized areas could help reduce the high rate of complications in immediate breast reconstruction.


Criteria:

Inclusion Criteria: 3.1.0 Ability to understand and the willingness to sign a written informed consent document. 3.1.1 Signed written informed consent. 3.1.2 Women with local or regional recurrences after previous breast conserving surgery. 3.1.3 Women undergoing delayed post mastectomy reconstruction. 3.1.4 Women undergoing prophylactic mastectomy. 3.1.5 Women with invasive or non-invasive breast cancer, receiving breast conserving surgery with or without reduction mammoplasty or mastectomy, with or without immediate reconstruction. 3.1.6 Women of 18 years of age or older. 3.1.7 ECOG or Karnofsky Performance Status 0,1,2. 3.1.8 Basic Metabolic Panel within 6 months 3.1.9 Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements. Exclusion Criteria: 3.2.1 History of liver or kidney failure will not be eligible. 3.2.2 Allergies to iodine containing products will not be eligible. 3.2.3 Women who are pregnant will not be eligible.


NCT ID:

NCT01315119


Primary Contact:

Principal Investigator
Geoffrey C. Gurtner
Stanford University

Shannon Meyer
Phone: (650) 724-1953
Email: smeyer27@stanford.edu


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States

Shannon Meyer
Phone: 650-724-1953
Email: smeyer27@stanford.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.